Work

Supplementary Figures 1-5 from Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figures 1-5

DOI: 10.1158/1078-0432.22472100

Authors: Diane Reidy-Lagunes, Neeta Pandit-Taskar, Joseph A. O'Donoghue, Simone Krebs, Kevin D. Staton, Serge K. Lyashchenko, Jason S. Lewis, Nitya Raj, Mithat Gönen, Christian Lohrmann, Lisa Bodei, Wolfgang A. Weber

Language: English

Topic: Neuroendocrine Tumor Research Advances

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361969590

Cites:

Cited by:

Related to: 10